TrialSignal
Clinical trial intelligence report
A 52-week, Phase III, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Currently ESA Users
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02969655
Status
COMPLETED
Phase
Phase III
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
The clinical trial evaluated the efficacy and safety of daprodustat compared to darbepoetin alfa in Japanese hemodialysis-dependent patients with anemia related to CKD. The study aimed to demonstrate non-inferiority of daprodustat to the standard treatment, darbepoetin alfa, over a 52-week period.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02969655
Indication
Anaemia
Modality
small molecule
Target
Anemia associated with Chronic Kidney Disease (CKD)
Intervention
Daprodustat small, Daprodustat small placebo, Daprodustat large, Daprodustat large placebo, Darbepoetin alfa, Darbepoetin alfa placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.